Welcome to The GeoWire , your source for a Peek into GeoInvesting’s Research Coverage, Microcap Stock Education, Case Studies, Featured Videos, and More. Please share this if you like today’s newsletter and comment with any feedback.

If you are new or this was shared with you, you can join our email list here.

By Maj Soueidan, Co-founder, GeoInvesting

This week, we’re highlighting clips from the Skull Session Interviews we just had with the management of two companies whose stocks just got more timely.

The first is a stock in our pipeline that we have been following since 2020.

It is listed in our Run2One Model Portfolio, a selection of stocks trading below $1.00 that we anticipate will surge beyond the $1.00 mark due to their current undervaluation and the potential for substantial revenue and net income growth.

I find it ridiculous that this profitable company with high recurring revenue and a low customer abandonment rate is trading at an absurdly low valuation. We think this acquisition is going to be the catalyst to take the stock over the dollar mark in the coming weeks. This would lead to an increase in the stock price of nearly 200%. You can see the full pitch on the stock here.

The second is a pharmaceutical company also selling at an absurdly low valuation. The company has a mound of cash, is aggressively buying back stock and just surprised the market by growing its earnings per share by over 100% in the third quarter of 2023.

—

If you are a premium subscriber and not currently logged in, you can log in here to view all the premium content associated with this Post. Once Logged in, Just click on The link for Issue No. 111 Listed At top of your Home Page.

If you are not a premium subscriber, please JOIN HERE.

—